$MDGL News

Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade)

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worries

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript

Madrigal Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate

Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark Office

BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026